Changes in the expression of genes encoding for mGlu4 and mGlu5 receptors and other regulators of the indirect pathway in acute mouse models of drug-induced parkinsonism

Neuropharmacology
Milena CannellaGiuseppe Battaglia

Abstract

Neuroadaptive changes involving the indirect pathway of the basal ganglia motor circuit occur in the early phases of parkinsonism. The precise identification of these changes may shed new light into the pathophysiology of parkinsonism and better define the time window of pharmacological intervention. We examined some of these changes in mice challenged with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), or with the dopamine receptor blocker, haloperidol. These two models clearly diverge from Parkinson's disease (PD); however, they allow an accurate time-dependent analysis of neuroadaptive changes occurring in the striatum. Acute haloperidol injection caused a significant increase in the transcripts of mGlu4 receptors, CB1 receptors and preproenkephalin-A at 2 and 24 h, and a reduction in the transcripts of mGlu5 and A2A receptors at 2 h. At least changes in the expression of mGlu4 receptors might be interpreted as compensatory because haloperidol-induced catalepsy was enhanced in mGlu4(-/-) mice. Mice injected with 30 mg/kg of MPTP also showed an increase in the transcripts of mGlu4 receptors, CB1 receptors, and preproenkephalin-A at 3 d, and a reduction of the transcript of A2A receptors at 1 d in the striatum. Genetic d...Continue Reading

References

Dec 7, 1992·Neuroscience Letters·P Mailleux, J J Vanderhaeghen
Sep 1, 1989·Journal of Neuroscience Methods·M Dragunow, R Faull
Jan 1, 1985·Pharmacology·G Zetler, G H Baumann
Dec 5, 1998·Neurochemistry International·K J Kovács
Dec 20, 2003·Annals of the New York Academy of Sciences·Michael J MarinoP Jeffrey Conn
Mar 27, 2004·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Lauren M Billings, John F Marshall
Mar 12, 2005·The Journal of Pharmacology and Experimental Therapeutics·Ornella ValentiMichael J Marino
Nov 9, 2005·Nature Reviews. Neuroscience·P Jeffrey ConnFerdinando Nicoletti
Jul 11, 2006·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Giuseppe BattagliaValeria Bruno
Aug 8, 2006·European Journal of Pharmacology·Naila IsmayilovaMichael J Dascombe
Oct 25, 2007·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Ana Belén MartínRosario Moratalla
Mar 3, 2009·Neurology·Jonathan Brotchie, Cheryl Fitzer-Attas
May 29, 2009·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Bernhard H MeurersClifford W Shults
Aug 26, 2009·CNS & Neurological Disorders Drug Targets·Kari A JohnsonColleen M Niswender
Feb 6, 2010·Journal of Neurochemistry·Bazoumana OuattaraThérèse Di Paolo
Jul 27, 2010·Nature Medicine·Francesca FallarinoRoberto Di Marco
Nov 3, 2010·Neuropharmacology·F NicolettiJ P Pin
Jun 26, 2012·Neuron·Nicolas MalletPeter J Magill
May 30, 2013·Molecular Pharmacology·Jordan MarroccoFerdinando Nicoletti
Oct 1, 2013·Neurobiology of Disease·Hilary Highfield Nickols, P Jeffrey Conn
Jan 2, 2014·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Shen YinColleen M Niswender

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Atypical Parkinsonism (MDS)

Atypical Parkinsonism presents with the same signs and symptoms of Parkinson's disease, but do not respond to typical Parkionson's disease treatment with levodopa. Atypical Parkinsonism is thought to be associated with abnormal protein buildup within brain cells. Here is the latest on Atypical Parkinsonism.

Basal ganglia in Parkinson's disease (MDS)

The basal ganglia is comprised of the neostriatum, the external and internal pallidal segments, the subthalamic nucleus, the substantia nigra pars reticulata, and the pars compacta of the substantia nigra. The basal ganglia circuitry is responsible for the correct execution of voluntary movements and is implicated in Parkinson's disease. Here is the latest research investigating the basal ganglia in Parkinson's disease.